You are here: Industry Insights > adalimumab

News List

Participants Dosed on Adessia in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa PharmaSources
March 07, 2023
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and overseas.
Biogen Welcomes NICE Announcement on TA375 as a Landmark Decision for UK Patients with Moderate Rheumatoid Arthritis firstwordpharma
June 11, 2021
Biogen UK welcomes the decision by the National Institute for Health and Care Excellence (NICE) to broaden patient access to biologics, including biosimilars, to treat moderate rheumatoid arthritis (RA).
EU authorises Celltrion’s adalimumab biosimilar Yuflyma pharmatimes
February 19, 2021
The European Commission has approved Celltrion Healthcare’s Yuflyma, a biosimilar to adalimumab – marketed by AbbVie as Humira.
Cadila Pharma launches Cadalimab (adalimumab biosimilar) for India expresspharma
August 31, 2020
Cadila Pharmaceuticals announced the launch of adalimumab biosimilar under the brand name Cadalimab for the domestic market.
The 2nd Chinese-Produced Adalimumab Biosimilar to be Approved for Marketing PharmaSources/Xiaoyaowan
January 08, 2020
From the current pattern in China, rather than the price war, Chinese-produced adalimumab biosimilars shall work on at least the following aspects: to strive to enter the NRDL to solve patients’ worries about payment; to strive for more indications to exp
Chinese Autoimmune Disease Drug Market: Which of the Competing Global Blockbuster Drugs Will Win? PharmaSources/1°C
December 05, 2019
Adalimumab has been “active” recently. Multiple adalimumab biosimilars are entering the harvest period in China following the arrival of China’s biosimilar era starting with ...
Breaking News! China’s Humira Biosimilar Produced by Bio-Thera to be Marketed Soon PharmaSources/Caicai
November 05, 2019
The marketing application of Bio-Thera’s adalimumab (acceptance No.: CXSS1800018) has recently been under the “under approval” status, which is expected to be approved for marketing soon for treating ankylosing spondylitis (AS).
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions drugs
September 26, 2019
In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement ...
Patent litigation for adalimumab resolved in the US europeanpharmaceuticalreview
May 29, 2019
AbbVie has announced that it has resolved its US HUMIRA (adalimumab) litigation with Boehringer Ingelheim.
Boehringer Ingelheim axes biosimilars development outside US pharmaphorum
December 06, 2018
Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible.

Previous page 1 2 Next page